SLC5A2 and hydrops fetalis: A recently published meta-analysis by Sinha et al evidenced the positive impact of SGLT2 inhibitor administration in AMI by curbing the risk of hospitalization for HF and cardiovascular mortality compared to placebo, with negligible effect on all-cause mortality[21].